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Summary. Analysis of longitudinal randomised controlled trials is frequently complicated
because patients deviate from the protocol. Where such deviations are relevant for the es-
timand, we are typically required to make an untestable assumption about post-deviation
behaviour in order to perform our primary analysis and estimate the treatment effect. In
such settings, it is now widely recognised that we should follow this with sensitivity anal-
yses to explore the robustness of our inferences to alternative assumptions about post-
deviation behaviour. Although there has been a lot of work on how to conduct such sen-
sitivity analyses, little attention has been given to the appropriate loss of information due
to missing data within sensitivity analysis. We argue more attention needs to be given to
this issue, showing it is quite possible for sensitivity analysis to decrease and increase the
information about the treatment effect. To address this critical issue, we introduce the con-
cept of information-anchored sensitivity analysis. By this we mean sensitivity analysis in
which the proportion of information about the treatment estimate lost due to missing data
is the same as the proportion of information about the treatment estimate lost due to miss-
ing data in the primary analysis. We argue this forms a transparent, practical starting point
for interpretation of sensitivity analysis. We then derive results showing that, for longitudi-
nal continuous data, a broad class of controlled and reference-based sensitivity analyses
performed by multiple imputation are information-anchored. We illustrate the theory with
simulations and an analysis of a peer review trial, then discuss our work in the context of
other recent work in this area. Our results give a theoretical basis for the use of controlled
multiple imputation procedures for sensitivity analysis.
Keywords: deviations, missing data, controlled multiple imputation, sensitivity anal-
ysis, randomised controlled trial
1. Introduction
The statistical analysis of longitudinal randomised clinical trials is frequently compli-
cated because patients deviate from the trial protocol. Such deviations are increasingly
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referred to as inter-current events. For example, patients might withdraw from trial
treatment, switch treatment, receive additional rescue therapy or simply become lost
to follow-up. Post-deviation, such patients’ data (if available) will often no longer be
directly relevant for the primary estimand. Consequently, such post-deviation data are
often set as missing; any observed post-deviation data can then inform the missing data
assumptions. Nevertheless, however the analysis is approached, unverifiable assumptions
about aspects of the statistical distribution of the post-deviation data must be made.
Recognising this, recent regulatory guidelines from the European Medicines Agency
Committee for Medicinal Products for Human Use (2010) and a United States Food and
Drug Administration mandated panel report by the National Research Council (2010)
emphasise the importance of conducting sensitivity analyses. Further, the recent publi-
cation of the International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH) E9 (R1) addendum on estimands
and sensitivity analysis in clinical trials (2017) raises important issues about how such
sensitivity analyses should be approached. It highlights how in any trial setting it is im-
portant first to define the estimand of interest. This will inform what data are missing
and how such missing data should be handled in the primary analysis. Sensitivity anal-
ysis, which targets the same estimand, should subsequently be undertaken to address
the robustness of inferences to the underlying assumptions, including those made for the
missing data.
We propose splitting sensitivity analyses for missing data into two broad classes. In
both classes, one or more alternative sets of assumptions (or scenarios) are postulated
and the sensitivity of the conclusions to these alternative scenarios is to be assessed. In
our first class, the primary analysis model is retained in the sensitivity analysis. This
enables the exclusive assessment of the impact of alternative missing data assumptions
on the primary outcome of interest. For example, for our sensitivity analysis we may
impute missing data under a missing not at random (MNAR) assumption, and fit the
primary analysis model to these imputed data. When performed by Multiple Imputation
(MI), class-1 sensitivity analyses are therefore uncongenial, in the sense described by
Meng (1994) and Xie and Meng (2017). Conversely, in the second class, for each set of
sensitivity assumptions an appropriate analysis model is identified and fitted. Hence,
each such analysis model is consistent with its assumptions, which is why the analysis
models generally change as we move from scenario to scenario.
In the first class of sensitivity analyses, the assumptions of the primary analysis model
may be inconsistent to some degree with the data generating mechanism postulated by
the sensitivity analysis assumption. Nevertheless, a strong advantage of such sensitiv-
ity analysis is the avoidance of full modelling under various, potentially very complex,
missing data assumptions. However, when performing class-1 sensitivity analyses, the
properties of an estimator under the primary analysis may change as we move to the
sensitivity analysis. In particular, we will see that a sensible variance estimator for
the primary analysis may behave in an unexpected way under certain sensitivity anal-
ysis scenarios, for example decreasing as the proportion of missing values increases. In
regulatory work, particularly in class-1 sensitivity analyses, it is therefore important
to appreciate fully the quantity and nature of any additional statistical information
about the treatment estimate that may arise in the sensitivity analysis, relative to the
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Fig. 1. Information about the sample mean varies with σ2m.
primary analysis.
This superficially abstract point can be readily illustrated. Suppose a study intends
to take measurements on n patients Y1, . . . , Yn, from a population with known variance
σ2, and the estimator is the mean. If no data are missing, then the statistical information
about the mean is n/σ2. Now suppose that nd observations are missing. We will perform
a class-1 sensitivity analysis, so that the estimator is the mean for both our primary and
sensitivity analysis. Our primary analysis will assume data are missing completely at
random, and the sensitivity analysis will assume that the missing values are from patients
with the same mean, but a different variance, σ2m.
Under our primary analysis assumption, we can obtain valid inference by calculating
the mean of the n−nd observed values, or by using multiple imputation for the missing
values. In both cases the information about the mean is the same: (n− nd)/σ2.
Under our class-1 sensitivity analysis, we multiply impute the missing data under
our assumption, and again our estimator is the mean. Now, however, the statistical
information will be approximately n2/{(n − nd)σ2 + ndσ2m}. Further, the information
about the mean from the sensitivity analysis depends on σ2m. Since σ
2
m is not estimable,
this information is under the control of the analyst.
This is illustrated by Figure 1, which shows how the information about the mean
varies with σ2m, when n = 100, nd = 20 and σ
2 = 1. When σ2m < σ
2, the information
about the mean in the sensitivity analysis is greater than from the intended 100 ob-
servations; when 1 ≤ σ2m ≤ 2.25 then the information is greater than in the (n − nd)
observations we were able to obtain, and when σ2m > 2.25, the information is less than
in the observed data (n− nd) observations we were able to obtain.
We believe the ICH E9 (R1) addendum (2017) will lead to sensitivity analysis playing
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a much more central role; in this context we believe it important for statisticians and
regulators to be aware of how—compared to the primary analysis—information can be
removed or added in the sensitivity analysis.
Our purpose in this paper is to:
1. Consider the information in sensitivity analyses, arguing that sensitivity analysis
in a clinical trial should be information-anchored—as defined below—relative to
the primary analysis, and
2. Demonstrate that using reference- and δ-based controlled multiple imputation, with
Rubin’s rules, to perform class-1 sensitivity analyses is information-anchored.
An important practical consequence of our work is that it provides a set of condi-
tions that can be imposed on class-1 sensitivity analyses to ensure that—relative to the
primary analysis—they neither create, nor destroy, statistical information. We believe
this provides important reassurance for their use, for example in the regulatory setting.
The plan for the rest of the paper is as follows. Section 2 defines the concept of
information-anchoring in sensitivity analysis. Section 3 considers class-1 sensitivity anal-
ysis by reference- and δ-based controlled multiple imputation, and presents our main the-
oretical results on information-anchoring within this setting. Section 4 briefly reviews
class-2 sensitivity analyses from this perspective. In Section 5 we present a simulation
study which illustrates our theory for information-anchored sensitivity analysis, which
is then applied to a trial of training for peer reviewers in Section 6. We conclude with a
discussion in Section 7.
2. Information-Anchored Sensitivity Analysis
We have seen in the simple example above how a sensitivity analysis can change the
statistical information about a treatment estimate. We now define information-anchored
sensitivity analyses, which hold the proportion of information lost due to missing data
constant across the primary and sensitivity analyses.
Suppose that a clinical trial intends to collect data from 2n patients, denoted Y, in or-
der to estimate a treatment effect θ. However, a number of patients do not give complete
data. Denote the observed data by Yobs, and missing data by Ymiss. Consistent with
the ICH-E9 (R1) addendum (2017), we make a primary set of assumptions, under which
we perform the primary analysis. We then make a sensitivity set of assumptions, under
which we perform the sensitivity analysis. Both primary and sensitivity assumptions (i)
specify the distribution [Ymiss|Yobs], (ii) could be true, yet (iii) cannot be verified from
Yobs.
Let θˆobs, primary be the estimate of θ under the primary analysis assumption. Further,
suppose we were able to observe a realisation of Ymiss under the primary assumption.
Putting these data together with Yobs gives us a complete set of observed data, which
actually follows the primary assumption: we denote this by Yprimary, and the corre-
sponding estimate of θ by θˆfull, primary. We denote the observed information about θ by
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I(θˆobs, primary) and I(θˆfull, primary), respectively. Then,
I(θˆobs, primary)
I(θˆfull, primary)
< 1,
reflecting the loss of information about θ due to missing data.
Defining corresponding quantities under the sensitivity assumptions for the chosen
sensitivity analysis procedure (be this class-1 or class-2) we have,
I(θˆobs, sensitivity)
I(θˆfull, sensitivity)
< 1,
again reflecting the loss of information about θ due to missing data—but now under the
sensitivity assumptions.
Comparing these leads us to the following definitions,
I(θˆobs, primary)
I(θˆfull, primary)
>
I(θˆobs, sensitivity)
I(θˆfull, sensitivity)
: Information-negative sensitivity analysis,
I(θˆobs, primary)
I(θˆfull, primary)
=
I(θˆobs, sensitivity)
I(θˆfull, sensitivity)
: Information-anchored sensitivity analysis, (1)
I(θˆobs, primary)
I(θˆfull, primary)
<
I(θˆobs, sensitivity)
I(θˆfull, sensitivity)
: Information-positive sensitivity analysis.
When analysing a clinical trial, we believe an information-positive sensitivity analysis
is rarely justifiable, implying as it does that the more data are missing, the more certain
we are about the treatment effect under the sensitivity analysis. Conversely, while
information-negative sensitivity analyses provide an incentive for minimising missing
data, there is no natural consensus about the appropriate loss of information. Therefore,
we argue that information-anchored sensitivity analyses are the natural starting point.
In regulatory work they provide a level playing field between regulators and industry,
allowing the focus to be on the average response to treatment among the unobserved
patients.
The definitions above are quite general, applying directly to class-1 and class-2 sen-
sitivity analyses, and all types of de jure (on-treatment) and de facto (as-observed) as-
sumptions. We now discuss class-1 sensitivity analyses from the information perspective
and present our theory for information-anchoring.
3. Class-1 Sensitivity Analysis and Theory for Information-Anchoring
While class-1 sensitivity analyses can be performed without using multiple imputation
(Lu, 2014; Liu and Pang, 2016; Tang, 2017), multiple imputation is the most flexi-
ble approach, and often the simplest to implement (e.g., using the SAS software from
www.missingdata.org.uk or Stata software by Cro et al. (2016)). This is generally called
controlled multiple imputation, because the form of the imputation for the missing data
is controlled by the analyst. So, for example, the analyst can control the imputed data
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mean to be δ below that under missing at random (MAR). See, for example, Mallinckrodt
(2013) Ch. 10, O’Kelly and Ratitch (2014), p. 284–319 and Ayele et al. (2014).
One approach is to obtain information about parameters that control the departure
from MAR from experts (Mason et al., 2017), but this is controversial (Heitjan, 2017),
and challenging for longitudinal data where multiple parameters are involved. An al-
ternative, as introduced by Little and Yau (1996) and developed and discussed further
more recently by, among others, Carpenter et al. (2013); Ratitch et al. (2013); Liu and
Pang (2016), is reference-based multiple imputation. In this approach, the distribution
of the missing data is specified by reference to other groups of patients. This enables
contextually relevant qualitative assumptions to be explored and avoids the need to for-
mally specify numerical sensitivity parameters (these are implicit consequences of the
appropriate reference for a patient). Some examples are listed in Table 1. For example,
we may explore the consequences of patients in an active arm ‘jumping to reference’
post-deviation. In practice the appropriate imputation model depends critically on the
particular clinical setting and what assumptions are considered credible. Such analyses
can be performed using the reference-based MI algorithm in Appendix A implemented
in Cro et al. (2016). Overall, this approach is both very flexible, and accessible, since
patients’ missing outcomes are specified qualitatively—by reference to other groups of
patients in the study. This explains its increasing popularity (Philipsen et al., 2015; Jans
et al., 2015; Billings et al., 2018; Atri et al., 2018).
The above papers all focus on clinical trials with continuous outcome measures that
are collected longitudinally, and modelled using the multivariate normal distribution.
We consider the same setting, and give criteria for class-1 sensitivity analysis using con-
trolled multiple imputation with Rubin’s variance formula to be information-anchored.
This shows that most forms of δ- and reference-based imputation proposed in the liter-
ature are, to a good approximation, information-anchored. It also shows that, in class-1
settings, uncritical use of the conventional primary analysis variance estimator is often
information-positive, which is undesirable in practice.
There are two principal reasons for this. The first is that class-1 sensitivity analyses
retain the primary analysis model in the sensitivity analysis. However, in the sensitivity
analysis data assumptions are not wholly compatible with those of the primary analysis
model. In particular variance estimators may behave in unexpected ways. The second
reason is that reference-based methods essentially use the data twice, for example, by
using data from the reference arm (i) to impute missing data in an active arm and (ii)
to estimate the effect of treatment in the reference arm.
3.1. Theoretical Results
The presentation of our theoretical results is structured as follows. We begin by describ-
ing our data, model, primary analysis and sensitivity analysis. We show in Corollary 2
that, when all data can be fully observed, for our treatment estimate θˆ,
E[Vˆfull, sensitivity] = E[Vˆfull, primary] +O(n
−2).
Theorem 1 then defines the information-anchored variance and derives a general expres-
sion for the difference between this and the variance from Rubin’s rules. Finally, we
show, in the remarks following the theorem, that in practice this difference is small.
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Table 1. Examples of reference-based and external information controlled multiple
imputation methods.
Name Description
Reference-based
controlled MI methods:
Jump to reference (J2R)
Imputes assuming that following dropout a patients mean
profile follows that observed in the reference arm.
Pre-drop out means come from the randomised arm.
Copy increments in
reference (CIR)
Forms post-dropout means by copying increments in the
reference arm. Pre-drop out means come from the
randomised arm.
Last mean carried
forward (LMCF)
Forms post-dropout means by carrying forward the
randomised arm mean at dropout.
Copy reference (CR)
The conditional profile given the history is copied from
the reference group i.e. imputes as if randomised to
reference arm, pre- and post-drop out means come from
the reference arm.
External information
controlled MI methods:
The δ-method
Impute under randomised arm MAR and subtract/add by
fixed δ.
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Trial Data
Consider a two-arm trial, which includes n patients randomised to an active arm and
n patients randomised to a reference arm (total 2n patients within the trial). Outcome
data are recorded at j = 1, ..., J visits, where visit j = 1 is baseline. For patient i in
treatment arm z, where z = a indicates active arm assignment and z = r indicates
reference arm assignment, let Yz,i,j denote the outcome at time j.
We wish to estimate the treatment effect at the end of the follow-up, time J. Our
analysis model is the regression of the outcome at time J on treatment and baseline (i.e.,
ANCOVA). Now suppose a number of patients are lost to follow-up in the active arm
(for simplicity, we assume for now the reference arm data are complete). Our primary
assumption is MAR.
Our primary analysis uses all the observed values, imputes the missing data under
MAR, fits the ANCOVA model to each imputed data set and combines the results (this
is essentially equivalent to fitting a mixed model with unstructured mean and covariance
matrix to the observed values, see Carpenter and Kenward (2008), Chapter 3).
Our sensitivity analysis uses controlled multiple imputation, as formally defined be-
low. This could include a δ-based method or one of the reference-based methods given in
Table 1; all reference-based MI methods can be implemented using the generic algorithm
in Appendix A.
For each trial arm, we assume a multivariate normal model, with common covariance
matrix, so that for patient i who has no missing values:
Yz,i,1
Yz,i,2
...
Yz,i,J
 ∼ N


µz,1
µz,2
...
µz,J
 ,Σ =

σ21,1 σ
2
1,2 . . . σ
2
1,J
σ21,2 σ
2
2,2 . . . σ
2
2,J
...
... . . .
...
σ21,J σ
2
2,J . . . σ
2
J,J

 ,
where z = a for the active patients and z = r for the reference patients.
Now suppose all reference group patients follow the protocol, but nd = n− no active
patients deviate from the protocol. Suppose it was possible to continue to observe these
nd patients, but now their post-deviation data follows the controlled model:
Ya,i,1
...
Ya,i,j−1
Ya,i,j
Ya,i,j+1
...
Ya,i,J

∼ N


µa,1
...
µa,j−1
µd,j,j
µd,j,j+1
...
µd,j,J

,Σ

. (2)
The term ‘controlled’ means that the analyst controls the post-deviation distribution.
Here, for patient i, the first index indicates active/deviation, the second the time of
deviation, and the third the visit number. Different patients can deviate at different
times, and this general formulation allows the pattern of their post-deviation means to
differ depending on their deviation time. This encompasses all the settings in Table 1,
and others besides.
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To present the theory, we first consider the case where the primary analysis does not
adjust for baseline, extending to the baseline-adjusted case in Corollary 2.
Proposition 1
For the trial data described above, when the analysis model is a difference in means
at the final time point with the usual sample variance estimate in both observed and
controlled settings, then:
(a) If all patients follow the protocol and no data are missing, then the expectation of
the variance estimate is:
E[Vˆfull, primary] =
2σ2J,J
n
.
(b) If nd patients deviate and are observed following the controlled model (2) the
expectation of the variance estimate is:
E[Vˆfull, sensitivity] =
2σ2J,J
n
+
J∑
j=2
nond,j∆
2
d,j
n3
+
J∑
p=2
J
q 6=p∑
q=2
nd,pnd,q∆
2
d,p,q
n3
,
where ∆d,j = µa,J − µd,j,J , ∆d,p,q = µd,p,J − µd,q,J and we let (n− 1)→ n.
Proof: Appendix B.1. 2
Corollary 1
For clinical trials designed to detect a difference of µa,J − µr,J = ∆, with a significance
level of α and power β, at the final visit, J,
E[Vˆfull, sensitivity] = E[Vˆfull, primary] +O(n
−2).
Proof:
First notice that the standard sample size formula implies
∆2 =
2f(α, β)σ2
n
.
Therefore, ∆2 is O(n−1). Further, since in any trial, all ∆2d,p,J can be written as ∆
2
d,p,J =
κd,p,J∆
2 for some constant κd,p,j , we have ∆
2
d,p,J = O(n
−1). Following the same argu-
ments, ∆2d,j = O(n
−1). Second, notice that no/n is the proportion of active patients
who complete the trial, and nd,j/n is the proportion who deviate at time j. Therefore,
nond,j/n
2 < 1. Similarly nd,pnd,q/n
2 < 1. It therefore follows that,
E[Vˆfull, sensitivity] = E[Vˆfull, primary] +O(n
−2). (3)
Corollary 2
Under the conditions of Corollary 1, if the primary analysis model is a linear regression
of the outcome at the final time point, adjusted for baseline, then (3) still holds.
Proof:
Replace the unconditional variance, σ2J,J , with the variance conditional on baseline,
σ2J.1 = σ
2
J,J −
(
σ21,J
)2
/σ21,1, in the proof of Proposition 1. 2
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We now use this result in the context of reference-based multiple imputation to calculate
the difference between our defined information-anchored variance and Rubin’s multiple
imputation variance.
Theorem 1
Consider a two-arm trial which includes n patients randomised to an active arm and n
patients randomised to a reference arm. Measurement data is recorded at j = 1, . . . , J
visits (where visit 1 is baseline). The primary analysis model is a linear regression of the
outcome at the final time point (visit J) on baseline outcome and treatment. Suppose
all n of the reference arm are completely observed on reference treatment over the full
duration of the trial (at all J visits) but in the active arm, only no are observed without
deviation. The remaining nd patients in the active arm deviate at some point during
the trial post-baseline in a monotone fashion (such that no + nd = n). Specifically, we
assume a proportion pid,j = nd,j/n drop out at each visit, for j > 1 and their data are
missing post-deviation.
Assume that the primary design-based analysis model satisfies (3), and that the
variance covariance matrix for the data is the same in each arm. For the patient deviation
pattern in the active arm beginning at time j, let P¯a,d,j be the j × 1 mean vector of the
nd,j responses at times 1, . . . , (j−1) plus a 1 (to allow for an intercept in the imputation
model).
Suppose the primary analysis is performed by MI assuming within-arm MAR. Let
Vˆobs, primary denote the estimated variance for the treatment effect under the primary
MAR assumption. Subsequently we perform class-1 sensitivity analysis via reference-
based MI, i.e. under (2), using the imputation algorithm in Appendix A. This general
formulation includes all the reference-based options in Table 1. As we are doing class-
1 sensitivity analysis, the primary analysis model is used to analyse the imputed data.
Then the difference between the information-anchored variance of the sensitivity analysis
treatment estimate, denoted by Vˆanchored, which by definition is (Vˆobs, primary/Vˆfull, primary) ×
Vˆfull, sensitivity and Rubin’s MI variance, denoted by VˆRubin’s, MI, is
E[Vˆanchored]−E[VˆRubin’s, MI] =
J∑
j=2
pi2d,jP¯a,d,j(Vprimary,j−Vsensitivity,j)P¯Ta,d,j+
E[Bˆprimary]
O(n2)E[Wˆprimary]
.
(4)
Here Vprimary,j is the variance-covariance matrix of the parameter estimates in the
primary MAR imputation model for deviation at time j and Vsensitivity,j is the variance-
covariance matrix of the parameter estimates in the imputation model for deviation
at time j, defined by the reference-based sensitivity analysis assumption. Bˆprimary is
the between-imputation variance and Wˆprimary is the within-imputation variance of the
treatment effect in the primary analysis, both under MAR.
Proof: Appendix B.2 2
Theorem 1 establishes the difference between the information-anchored variance and
Rubin’s rules variance. To show that class-1 sensitivity analysis by reference-based
multiple imputation is information-anchored, we need to consider how close expression
(4) is to zero.
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The key quantity driving the approximation is the first of the two terms. Notice
that for each deviation time, j, the variance covariance matrix of the parameters of the
on-treatment imputation model is Vprimary,j = Σj/no, where Σj is the relevant sub-
matrix of the variance-covariance matrix Σ of the J observations. The precise form of
Vsensitivity,j will depend on the sensitivity analysis imputation model. Consider data
from the fully observed reference arm are used in the sensitivity imputation (e.g. copy
reference). In this case, Vsensitivity,j = Σj/n, and
pi2d,jP¯a,d,j [Vprimary,j −Vsensitivity,j ]P¯Ta,d,j = pi2d,jP¯a,d,jΣj
[
1
no
− 1n
]
P¯
T
a,d,j
= pi2d,jP¯a,d,jΣj
[
n−no
non
]
P¯
T
a,d,j
= pi2d,jP¯a,d,jΣj
[
pid
n(1−pid)
]
P¯
T
a,d,j .
Applying this line of argument to the other methods in Table 1 suggests that the error
in the approximation will be small, and vanish asymptotically.
Thus we have established that class-1 referenced-based imputation sensitivity analysis
is, to a good approximation, information-anchored. We illustrate this in the simulation
study in Section 5.
3.2. Further Comments
(a) In the proof of Theorem 1, to simplify the argument, the variance-covariance matrix
of the data Σ is assumed known in the imputation model. When—as will generally
be the case—it has to be estimated, Carpenter and Kenward (2013), p. 58–59,
show that, for the simple case of the sample mean, the additional bias is small, and
vanishes asymptotically. This strongly suggests that any additional bias caused
by estimating the variance covariance matrix will be small, and asymptotically
irrelevant; this is borne out by our simulation studies below.
(b) For simplicity the theory treated the deviation pattern as fixed. We can replace all
the proportions, pid,j by their sample estimates, and then take expectations over
these in a further stage. As our results are asymptotic, the conclusions will be
asymptotically equivalent.
(c) δ-method sensitivity analysis: We consider that at the final time point J imputed
values for patients who deviate at time j (for j > 1) are edited by (J + 1 − j)δ
to represent a change in the rate of response of δ per time point post-deviation.
We now evaluate the size of the two terms in (4) separately. For the first term,
when δ is fixed, the covariance matrix for the imputation coefficients under the
primary analysis and the sensitivity analysis is identical for each missing data pat-
tern j; the δ-method simply adds a constant to the imputed values. Consequently
Vprimary,j = Vsensitivity,j , thus pi
2
d,jP¯a,d,j [Vprimary,j −Vsensitivity,j ]P¯Ta,d,j = 0, and
Rubin’s rules give a very sharp approximation to the information-anchored vari-
ance.
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However when δ is not fixed and we vary δ over the imputation set K, that is we
suppose δk ∼ N
(
δ, σ2δ
)
, then, pi2d,jP¯a,d,j [Vprimary,j −Vsensitivity,j ]P¯Ta,d,j = −pi2dσ2δ ,
and the sensitivity analysis is information-negative. The extent of this is principally
driven by the variance of δk.
Now consider the second term in (4). When the δ-method is used it is not necessarily
the case that (3) holds, since ∆d,j = µa,J − µd,j,J and ∆d,p,q = µd,p,J − µd,q,J are
not necessarily O(n−1). In the δ-based scenario, as outlined in Appendix B.1,
Vˆfull, sensitivity = Vˆfull, primary +Q,
where,
Q =
J∑
j=2
nond,j (J + 1− j)2 δ2
n3
+
J∑
p=2
(J,q 6=p)∑
q=2
nd,pnd,q ((J + 1− p) δ − (J + 1− q) δ)2
n3
.
Thus, for the δ-method the O(n−2) component in the second term of (4) is replaced
with Q (as defined above). The composition of Q indicates that the information-
anchoring performance of Rubin’s variance estimate will also depend on the size
of δ. Typically, the size of δ will not have a large effect since the terms in Q are
all multiplied by components of the form nond,j/n
3 or nd,pnd,q/n
3 and thus will
vanish asymptotically. Hence with a fixed δ adjustment, the information-anchoring
approximation will be excellent.
(d) Improved information-anchoring: Remark (b) shows that, provided the underlying
variance-covariance matrices of the data are similar, the key error term in the
information-anchoring approximation is the difference in precision with which they
are estimated. If all n patients are observed in the reference arm and no in the
active arm, this is
1
no
− 1
n
.
This suggests Rubin’s rules will lead to improved information-anchoring if, instead
of using all patients in the reference arm to estimate the imputation model for
deviators at time j, a random no are used. We have confirmed this by simulation,
but the improvement is negligible when the proportion of missing data is < 40%,
when simulations confirm the approximation is typically excellent.
(e) Theorem 1 suggests that, for a given deviation pattern, information-anchoring will
be worse the greater the difference between the covariance matrix of the imputa-
tion coefficients under the primary and sensitivity analysis. However, we have not
encountered examples where this has been a practical concern.
(f) We have not presented formal extensions of our theory to the case when we also
have missing data in the reference arm. But this does not introduce any substantial
errors in the information-anchoring approximation. With missing data in the refer-
ence arm, for each missing data pattern j, an additional component which depends
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on the difference between the variance of the imputation parameters in the primary
on-treatment imputation model and sensitivity scenario imputation model for the
reference arm, multiplied by the proportion of reference patients with that missing
data pattern squared (denoted pi2r,d,j) is included. If reference arm data are imputed
under within-arm MAR (as under CIR, CR or J2R) these terms will be zero. In
the more general case, where different patterns of patients, across different arms,
are imputed with different reference-based assumptions, additional non-zero error
terms of the form as in the summation in (4) will be introduced; but again, for the
reasons discussed above, these will typically be small. The covariance between the
parameters of the active and reference arm sensitivity scenario imputation models
for each missing data pattern also contributes to the sharpness of the approxima-
tion. The exact size of these additional error terms again depend on the specific
sensitivity scenario and in some cases will be zero (e.g. LMCF). But each covari-
ance term is always multiplied by the proportion of deviators in each arm with
the associated missing data patterns (pid,jpir,d,j), P¯a,d,j and P¯
T
r,d,j (the j × 1 mean
vector of the responses at times 1, . . . , (j − 1) for the reference patients deviating
at time j, plus a 1 to allow for an intercept in the imputation model). Thus will
be of a relatively small order in practice following the reasons discussed above.
Summary
Given a primary design-based analysis model, we have established in Proposition 1 a
criterion which defines a general class of reference-based sensitivity analyses. If these
sensitivity analyses are performed by MI, we have further established in Theorem 1
that they will be—to a good approximation—information-anchored, in line with the
principles we set out in Section 2. We have also shown why the information-anchoring
is particularly sharp for the δ-method of MI.
4. Class-2 Sensitivity Analyses and Information-Anchoring
A full exploration of information-anchoring for class-2 sensitivity analyses is beyond
the scope of this article. Here, we focus on likelihood-based selection models (see, for
example, Diggle and Kenward, 1994), and use the results of Molenberghs et al. (1998) to
make links to pattern mixture models, which allows us to use the results we presented
in Section 3.
Continuing with the setting in Section 3, consider a trial with scheduled measurement
times of a continuous outcome measure at baseline and over the course of the follow-
up. When data are complete, the primary analysis is the ANCOVA of the outcome
measure at the scheduled end of follow-up on baseline and treatment group. Equivalent
estimates and inferences can be obtained from a mixed model fitted to all the observed
data, provided we have a common unstructured covariance matrix and a full treatment-
time and baseline-time interaction.
Now suppose patients withdraw before the scheduled end of follow-up, and subsequent
data are missing. The mixed model described in the previous paragraph then provides
valid inference under the assumption that post-withdrawal data are MAR given base-
line, treatment group and available follow-up data. A selection model that allows post-
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withdrawal data to be MNAR combines this mixed model with a model for the dropout
process. Let Ri,j = 1/0 if we observe/miss the outcome for patient i at scheduled visit
j = 1, . . . , J. An illustrative selection model is:
Yi,j = αj + βjYi,0 + γjTi + i,j , i ∼ N(0,ΣJ×J)
g(Ri,j) = α
R
j + β
R
j Yi,0 + γ
R
j Ti + δ
R
1 Yi,j−1 + δR2 (Yi,j − Yi,j−1), (5)
where the superscript ‘R’ denotes a selection model parameter, and the link function
g is typically logit, probit or complementary log-log (the latter giving a discrete time
proportional hazards model for withdrawal).
Usually there is little information on the informative missingness parameter δR2 in
the data (Rotnitzky et al., 2000; Kenward, 1998), and this information will be highly
dependent on the assumed data distribution. Therefore, in applications it is more useful
to explore the robustness of inferences to specific, fixed, values of δR2 (δ
R
2 = 0 corresponds
to MAR).
For each of these specific values of δR2 , we may recast the selection model as a pattern
mixture model, following Molenberghs et al. (1998). The differences between the ob-
served and unobserved patterns are defined as functions of the fixed δR2 . However, these
then become a particular example of the δ-method pattern mixture models considered
in Section 3, which we have shown are information-anchoring.
More generally, local departures from MAR are asymptotically information-anchored.
To see this, denote by θ the parameters in (5), apart from δR2 . For a fixed δ
R
2 , let i(θˆ; δ
R
2 )
be the observed information matrix at the corresponding maximum likelihood estimates
θˆ. For regular log-likelihoods and a given data set, as we move away from MAR, for each
element, i, of the information matrix i, the mean value theorem gives
i(θˆ; δR2 )− i(θˆ; 0) =
(
∂
∂δR2
i(θˆ; δR2 )
∣∣∣∣
δR2 =δ˜
R
2
)
δR2 , for some δ˜
R
2 ∈ (0, δR2 ). (6)
However, asymptotically the parameter estimates are normally distributed, so the third
derivative of the likelihood (i.e. the RHS of (6)) goes to zero. Because the above holds
when we use both the full data, and the partially observed data, it is sufficient to give
information-anchoring. This is the basis for our intuition that, for most Phase III trials,
class-2 sensitivity analyses can be treated as information-anchored for practical purposes.
5. Simulation Study
We now present a simulation study which illustrates the information-anchoring property
of Rubin’s variance formula, derived in Section 3. The simulation study is based on
a double-blind chronic asthma randomised controlled trial conducted by Busse et al.
(1998). The trial compared four doses of the active treatment budesonide against placebo
on forced expiratory volume (FEV1 recorded in litres) over a period of 12 weeks. FEV1
measurements were recorded at baseline and after 2, 4, 8 and 12 weeks of treatment.
The trial was designed to have 80% power (5% type-1 error) to detect a change of 0.23
litres in FEV1 with 75 patients per arm, assuming a SD of 0.5 litres.
We simulated longitudinal data, consisting of baseline and two follow-up time points
(time 2 being week 4, and time 3 being week 12), from a multivariate normal distribution
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whose mean and covariance matrix were similar to those observed in the placebo and
lowest active dose arm of this trial:
Σplacebo = Σactive =
 0.4 0.2 0.20.2 0.5 0.2
0.2 0.2 0.6
 ,
µplacebo = [2.0, 1.95, 1.9] , µactive = [2.0, 2.21, µa,3] (litres).
In the asthma study µa,3 ≈ 2.2 litres, corresponding to a treatment effect of ≈ 0.3
litres at time 3 (week 12). In the simulation study we explored µa,3 = {1.9, 2.2, 2.9} .
To test the approximation (3) we chose a sample size of n = 250 in each arm, giving a
power of at least 90% in all scenarios. For each scenario, the analysis model was a linear
regression of FEV1 at visit 2 and baseline and treatment, and this was fitted to the full
data.
Subsequently, for the active arm, we simulated monotone deviation completely at
random. We varied the proportion of patients deviating overall from 0-50%. For each
overall proportion deviating, around half the patients deviated completely at random
before visit 2, and around half deviated completely at random before visit 3. All post-
deviation data were set to missing. The reference arm was always fully observed.
For each simulated data set, the primary analysis assumed MAR, and we performed
class-1 sensitivity analyses using each of the reference-based methods in Table 1. Fifty
imputations were used for each analysis. For the δ-method, the unobserved data was
postulated to be worse (than under MAR) by a fixed amount of δ = {0,−0.1,−0.5,−1},
for each time point post-deviation, where δ = 0 is equivalent to the primary, MAR
analysis. Thus, for patients who deviated between visits 1 and 2, their MAR imputed
observations at visit 2 were altered by δ and at time 3 by 2δ. For patients who deviated
between visits 2 and 3, their MAR imputed observation at time 3 was altered by δ.
One thousand independent replicates were generated for each combination of µa,3
and deviation. Our results focus on the visit 3 treatment effect and its variance.
In order to minimise the Monte-Carlo variability in our comparisons, we used the
same set of 1000 datasets and deviation patterns for each sensitivity analysis.
Within each replication, for each sensitivity scenario, we also drew post-deviation
data under this scenario, giving a complete scenario-specific data set. For each replica-
tion this allowed us to estimate the treatment effect and Vˆfull, sensitivity for each scenario.
Then, we calculated the theoretical information-anchored variance, which by definition
in Section 2 is Vˆanchored = (Vˆobs, primary/Vˆfull, primary)× Vˆfull, sensitivity. Rubin’s variance estimate
was calculated. Estimates were averaged over the 1000 simulations. All simulations
were performed using Stata version 14 (StataCorp, 2015) and reference-based MI was
conducted using the mimix program by Cro et al. (2016).
5.1. Simulation Results
Figure 2 shows the results, for each of the reference-based sensitivity scenarios in Table
1, and controlled multiple imputation with four values of δ.
The top four panels are for a moderate treatment effect of 0.3 (µa,3 = 2.2), compa-
rable to that found in the asthma trial. We see the results show excellent information-
anchoring by Rubin’s variance estimator for up to 40% of patients deviating. Notice the
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Fig. 2. Simulation results: for each sensitivity scenario, as the proportion of active arm devia-
tions increases, each panel shows the evolution of the mean estimate of the visit 3 treatment
effect variance (over 1000 replications) calculated in four ways: (i) −◦− Rubin’s MI variance, from
reference-/δ-based MI; (ii) −×− information-anchored variance (Eˆ[Vˆanchored]); (iii) −− applying pri-
mary analysis variance estimator in sensitivity scenarios; (iv) −/− Variance when post-deviation
data is actually fully observed under the given scenario (Eˆ[Vˆfull, sensitivity]).
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information-anchored variance is always greater than Vˆfull, sensitivity, the variance we would
see if we were able to observe data under the sensitivity assumption.
These results are echoed by those with smaller and larger treatment effects (see
Appendix C Figure 4). We conclude that, for realistic proportions of missing post-
deviation data, reference-based multiple imputation using Rubin’s variance estimator
can be regarded as information-anchored.
This is in contrast to the behaviour of the conventional variance estimator from the
primary regression analysis. Across all four reference-based scenarios, this gets smaller—
and tends to zero—as the proportion of missing data increases, so yields increasingly
information-positive inference as more data are missing! It is also smaller than the
variance we would obtain if we were able to observe data under the sensitivity assumption.
Therefore, (see Carpenter et al. (2014)) we believe this is not generally an appropriate
variance estimator for class-1 sensitivity analyses. We return to this point below.
Now consider the lower four panels of Figure 2, which show results for controlled
multiple imputation using the δ-method. Again, consistent with the theory in Sec-
tion 3, these show excellent information-anchoring by Rubin’s variance estimator for all
missingness scenarios for δ = 0,−0.1,−0.5 litres. Indeed, the information-anchoring ap-
proximation is better than for the reference-based methods above because the covariance
matrix for the imputation coefficients under MAR and δ-based imputation are identical:
term 1 in (4) disappears.
For contextually large δ = −1 litres, the approximation is excellent for up to 40%
missing data. For greater proportions of missingness the approximation is not so sharp,
and this is caused by the size of the second term in (4), which is larger with a bigger δ
and greater proportion of missing post-deviation data.
For the δ-method we also see using the conventional variance estimator from the
primary analysis is also information-anchored. The reason for different behaviour here
than for reference-based methods is that reference-based methods borrow information
from another trial arm, and they do this increasingly as the proportion of patients
deviating increases. This causes the conventional variance estimator to be information-
positive. However, with the δ-method there is no borrowing between arms, so this issue
does not arise.
To summarise, the simulations demonstrate our theoretical results, showing that for
all the controlled MI methods outlined in Table 1 (reference- and δ-based), in realistic
trial settings multiple imputation using Rubin’s rules gives information-anchored infer-
ence for treatment effects. It is only with very high proportions of missing data (e.g.
> 50%) that the information-anchoring performance of Rubin’s variance begins to dete-
riorate. Such high proportions of missing data are unlikely in well designed trials, and
would typically be indicative of other major problems.
6. Analysis of a Peer Review Trial
We now illustrate how the information-anchored theory outlined in Section 3 performs in
practice, using data from a single blind randomised controlled trial of training methods
for peer reviewers of the British Medical Journal. Full details of the trial are given in
Schroter et al. (2004).
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6.1. Description of the Data
Following concerns about the quality of peer review, the original trial was set up to eval-
uate no-training, face-to-face training or a self-taught training package. After consent,
but before randomisation, each participant was sent a baseline paper to review (paper
1) and the review quality was measured using the Review Quality Index (RQI). This is
a validated instrument which contains eight items and is scored from 1 to 5, where a
perfect review would score 5. All 609 participants who returned their review of paper 1,
were randomised to receive one of the three interventions.
Two to three months later, participants were sent a further article to review (paper
2). If this paper was reviewed a third paper was sent three months later (paper 3).
Unfortunately, not all of the reviewers completed the required reviews, thus a number
of review scores were missing. The main trial analysis was conducted under the MAR
assumption, using a linear regression of RQI on intervention group adjusted for baseline
RQI. The analysis showed that the only statistically significant difference was in the
quality of the review of paper 2, where the self-taught group did significantly better
than the no-training group.
Therefore, here we focus on examining the robustness of this purportedly significant
result to different assumptions about the missing data. Assuming MAR, the analysis
found that reviewers in the self-taught group had a mean RQI 0.237 points above the
no-intervention group (95% CI 0.01–0.37, p = 0.001). Although this is relatively small,
the self-taught intervention is inexpensive and may be worth pursuing. However, Figure
3 shows the quality of the review at baseline for (a) those who went on to complete the
second review and (b) those who did not, for each of these two trial arms. The results
suggest that a disproportionate number of poor reviewers in the self-taught group failed
to review paper 2. This suggests the MAR assumption may be inappropriate, and data
may be missing not at random.
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6.2. Statistical Analysis
The primary analysis model was a linear regression of paper 2 RQI on baseline and
intervention group (self-taught vs no-training), and the intervention effect estimate is
shown in the first row of Table 2.
We conducted four further analyses:
(a) We multiply imputed the missing RQI data assuming MAR, fitted the primary
analysis model to each imputed dataset and combined the results for inference using
Rubin’s rules. The imputation model for RQI of paper 2 included the variables
present in the primary analysis model (RQI at baseline and treatment group).
(b) As it is reasonable to suppose that many of the reviewers in the self-taught group
who did not return their second review ignored their training materials, we perform
a class-1 sensitivity analysis assuming they ‘copied no-training’. We used MI and
Rubin’s rules for information-anchored inference.
(c) We reproduced a previous sensitivity analysis described by White et al. (2007).
They used a questionnaire to elicit experts’ prior opinion about the average differ-
ence in review quality index between those who did, and did not, return the review
of paper 2 (20 editors and other staff at the BMJ completed the questionnaire). The
resulting distribution can be summarised as N(−0.21, 0.462). We used this to per-
form a δ-method sensitivity analysis, where, for each imputation k, RQI values in
the self-taught arm were imputed under MAR and then had δk ∼ N(−0.21, 0.462)
added. This analysis is expected to be information-negative.
(d) Our fourth analysis used the δ-method via MI for participants in the self-taught
arm, but now fixed δ = −0.21 (the mean expert opinion) to obtain information-
anchored analysis.
All analyses used 50 imputations and were performed using Stata version 14 (StataCorp,
2015).
6.3. Results
Table 2 shows the results. As theory predicts, rows 1 and 2 show that the primary
analysis and analysis assuming MAR using MI give virtually identical results. In row
3, reference-based sensitivity analysis assuming copy no-training reduces the estimated
effect to 0.172; compared to the primary analysis the information-anchored standard
error (SE) is now very slightly reduced at 0.069. The effect of this is to increase the
p-value by a factor of ten to 0.013.
In contrast, using the expert’s prior distribution (row 4), the point estimate is 0.195,
but the standard error is much increased at 0.132, so the p-value is over 100 times greater
than in the primary analysis. Lastly (row 5), again using the δ-method, but now fixing
δ = −0.21 gives a similar point estimate, but an information-anchored SE of 0.072.
Critically, comparing rows 4 and 5 shows that expert opinion loses a further
1
0.0722 − 10.1322
1
0.0722
= 70%
of the information beyond that lost due to missing data under the primary analysis. Such
information losses are not atypical (Mason et al., 2017). Since trials are often powered
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Table 2. Estimated effect of self-training vs no train-
ing on the paper 2 Review Quality Index, from the
primary and various sensitivity analyses; † indicates
information-anchored analysis.
Analysis Est SE p-value
Primary analysis, MAR† 0.237 0.070 0.001
MI, MAR† 0.234 0.071 0.001
MI, copy no-training† 0.172 0.069 0.013
MI, expert opinion 0.195 0.132 0.145
δk ∼ N(−0.21, 0.462)
MI, δ-method with 0.189 0.072 0.009
δ = −0.21†
with minimal regard to potential missing data, such a loss of information must frequently
lead to the primary analysis being overturned. By contrast, information-anchored sen-
sitivity analysis fixes the loss of information across the primary and sensitivity analysis,
at a level that is possible to estimate a-priori for any given deviation pattern.
7. Discussion
The recent publication of the ICH E9 (R1) addendum (2017) is bringing a sharper focus
on the estimand. As the addendum recognises, this in turn leads to greater focus on
the assumptions underpinning estimands. When we are faced with estimand relevant
protocol deviations, or inter-current events (e.g. rescue medication) and loss to follow-up
etc., such assumptions are at best only partially verifiable from the actual trial data.
In such settings, a primary analysis assumption is made, and then the robustness of
inferences to a number of secondary sensitivity assumptions will ideally be explored.
The assumptions underpinning the primary and sensitivity analyses should be as
accessible as possible. This applies not only to assumptions about the typical, or mean,
profile of patients post-deviation, but also to assumptions about their precision.
In this article, we have introduced the concept of information-anchoring—whereby
the extent of information loss due to missing data is held constant across primary and
sensitivity analyses. We believe this facilitates informed inferences and decisions, what-
ever statistical method is adopted. Information-anchoring allows stakeholders to focus
on the assumptions about the mean responses of each patient, or group of patients,
post-deviation, without being concerned as to whether we are injecting information
into or removing information from the analysis (relative to that lost—due to patient
deviations—in the primary analysis). For example, we believe this provides a good basis
for discussions between regulators and pharmaceutical statisticians: the former can be
reassured the sensitivity analysis is not injecting information, while the latter can be
reassured that the sensitivity analysis is not discarding information.
We have differentiated between two different types of sensitivity analysis: class-1 and
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class-2. In class-1 the primary analysis model is retained in the sensitivity analysis; such
sensitivity analyses can be readily (but need not be) carried out by multiple imputation.
Controlled MI procedures, which combine a pattern-mixture modelling approach with
MI, naturally fall into this first class. These include reference-based MI procedures,
which impute missing data under qualitative assumptions for the unobserved data, based
on data observed in a specified reference group. The primary analysis model is retained
in the sensitivity analyses, fitted to each imputed data set and results combined using
Rubin’s rules. Consequently the assumptions of the primary analysis model are gen-
erally inconsistent with the data generating mechanism postulated by the sensitivity
analysis assumption. Thus the usual justification for Rubin’s MI rules does not hold.
Instead, we have identified a new property of these rules, namely that for a broad class
of controlled MI approaches, including both δ- and reference-based approaches, they
yield information-anchored inference. In this regard, a practically important corollary
of our theory is that the widely used δ-method (and associated tipping-point analysis)
is information-anchored with fixed δ adjustment.
While we believe information-anchored sensitivity analyses provide a natural starting
point, and will often be sufficient, in certain scenarios it may also be desirable to conduct
information-negative sensitivity analysis. In such analyses a greater loss of information
due to post-deviation (missing) data is imposed by the analyst in the sensitivity analysis
relative to the primary analysis. One way to do this is by prior elicitation—i.e. incor-
porating a prior distribution on δ—as touched upon in the further comments following
Theorem 1 and Section 6. The theory in Section 3 also shows how a greater loss of infor-
mation can be imposed in sensitivity analysis via reference-based MI if required. This
is done by reducing the size of the reference group used to construct the reference-based
imputation models.
Whatever approach is taken, careful thought needs to be given, and justification
provided, for the additional loss of information being imposed. As we discussed at the
end of Section 6, the loss of information with prior elicitation can be substantial. Often
it will be difficult to justify an additional amount of information loss to impose.
Conversely, we argue that information-positive sensitivity analysis, where a lower loss
of information due to missing data post-deviation is imposed in the sensitivity analysis
relative to the primary analysis, is rarely justifiable, if at all. This is because it goes
against all our intuition that missing data means we lose (not gain) information: with
information-positive sensitivity analyses, we gain more precise inferences the more data
we lose!
Our approach to determining the appropriate information in sensitivity analyses
(which, as the simple example in the Introduction shows is under the control of the
analyst), contrasts with some recent work. Lu (2014), Tang (2017) and Liu and Pang
(2016) each developed alternative implementations of the reference-based pattern mix-
ture modelling approach. Lu (2014) introduced an analytical approach for placebo-based
(CR) pattern mixture modelling which uses maximum likelihood and the delta method
for treatment effect and variance estimation. Tang (2017) derived different analytical
expressions for reference-based models, also via the likelihood-based approach. Liu and
Pang (2016) proposed a Bayesian analysis for reference-based methods which estimates
the treatment effect and variance from the posterior distribution.
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What these papers have in common is that, in the terminology developed here, they
essentially choose to apply the primary analysis variance estimator across the sensitivity
analyses. While this choice has a long-run justification, for the reference-based multiple
imputation estimator, as our simulation results in Figure 2 show (and we have discussed
elsewhere (Carpenter et al., 2014)), this choice also means information-positive inferences
for reference-based scenarios. This is a consequence of (i) uncongeniality between the
imputation and analysis model and (ii) the fact that reference-based methods borrow
information from within and across arms. Thus we highlight here that if one of these
alternative implementations is employed within sensitivity analysis information-positive
inference will be obtained.
What are the implications of this for our approach? Necessarily, the variance estimate
arising from the information-anchored sensitivity analysis via reference-based multiple
imputation does not have a long-run justification for the reference-based multiple im-
putation point estimate. However, having determined that the information-anchored
variance is appropriate, we can readily inflate the long-run variance of the reference-
based multiple imputation estimator by adding appropriate random noise. In this way,
having chosen to make our primary and sensitivity analysis information-anchored, we
can derive a corresponding point estimator whose long run variance is the information-
anchored variance.
If we wish to do this, we can proceed as follows. Recall that reference-based methods
calculate the means of the missing values for each patient as linear combinations of the
estimated treatment means at each time point under randomised arm MAR. Assume
J follow-up visits, and denote these estimated means by the 2J × 1 column vector µ,
with estimated covariance matrix Vˆ. It follows that, for some 2J × 1 column vector
L, the maximum likelihood reference-based treatment estimate is given by Ltµ, with
associated estimated empirical variance σˆ2ML = L
tVˆL. If we denote the information-
anchored variance by σˆ2IA, take a draw from N(0, σˆ
2
IA− σˆ2ML), add this to the treatment
estimate obtained from the reference-based analysis by MI, this will result in an estimate
with the information-anchored variance in a long-run sense. In practice σˆ2ML could also
be estimated using one of the implementations of Lu (2014), Tang (2017) or Liu and
Pang (2016). In applications, however, we do not think this step is typically worthwhile.
Note too that with the δ-method σˆ2IA is well approximated by σˆ
2
ML, so it is not necessary.
This article has focused on the analysis of a longitudinal measure of a continuous
outcome. For generalized linear models (GLMs), if we perform controlled MI on the
linear predictor scale, then we can apply the theory developed here on the linear predictor
scale. This suggests that for GLMs, controlled MI will be approximately information-
anchored; preliminary simulations support this, and work in this area is continuing.
We note, however, that issues may arise with non-collapsability when combining the
component models in this setting. For survival data, we need to define the reference-
based assumptions. This has been done in a recent manuscript we have submitted, which
also contains simulation results suggesting promising information-anchoring properties
for Rubin’s rules in this setting.
When conducting class-1 sensitivity analyses via MI a natural question might be how
many imputations to conduct. As remarked in the proof of Theorem 1 in Appendix B.2,
the number of imputations does not materially affect the information-anchoring perfor-
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mance of Rubin’s variance estimate. Thus we recommend determining the number of
imputations required for primary analysis (under MAR) based on the required precision;
these should estimate the information-anchored variance with similar precision in sen-
sitivity analysis. To establish the number of imputations required to achieve a specific
level of precision under MAR Rubin (1987) showed that the relative variance i.e. the
efficiency of an estimate using only K imputations compared to an infinite number is
approximately (1+λ/K), where λ is the fraction of missing information. As discussed in
Carpenter and Kenward (2008), p. 86–87, 5–10 imputations is sufficient to get a reason-
ably accurate answer for most applications. For more critical inferences, at least 50-100
imputations are recommended (see Carpenter and Kenward, (2013), p. 54–55).
Of course, to obtain information-anchored analyses Multiple Imputation does not
have to be used. In principle we can perform information-anchored analysis by calculat-
ing the variance directly from the information-anchoring formula. However, to do this
we need to calculate the expected value of the design-variance when we actually observe
data under the sensitivity assumption. When the approach is used with its full flexibility
(with different assumptions for different groups of patients) this is awkward. Multiple
imputation provides a much more direct, computationally general, accessible approach
for busy trialists, without the need for sophisticated one-off programming which is often
required to directly fit MNAR pattern-mixture models or other MNAR models.
In conclusion, we believe that sensitivity analysis via controlled MI provides an ac-
cessible practical approach to exploring the robustness of inference under the primary
assumption to a range of accessible, contextually plausible alternative scenarios. It
is increasingly being used in the regulatory world (see, for example, the DIA pages
at www.missingdata.org.uk, and the code therein; Philipsen et al. (2015), Jans et al.
(2015), Billings et al. (2018), Atri et al. (2018), O’Kelly and Ratitch (2014) and refer-
ences therein). Our aim has been to provide a more formal underpinning. Information-
anchoring is a natural principle for such analysis, and we have shown this is an automatic
consequence of using MI in this setting.
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A. Appendix A: Algorithm for reference-based multiple imputation
For a continuous outcome, the generic algorithm of Carpenter et al. (2013) can be sum-
marized in full as follows:
(a) Separately for each treatment arm take all the observed data, and assuming MAR,
fit a multivariate normal (MVN) distribution with an unstructured mean (i.e. a
separate mean for each of the baseline and post-randomisation observation times)
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and variance covariance matrix using a Bayesian approach with an improper prior
for the mean and an uninformative Jeffreys prior for the covariance matrix.
(b) Draw a mean vector and covariance matrix from the posterior distribution for
each treatment arm. Specifically we use the Markov-Chain Monte Carlo (MCMC)
method to draw from the appropriate Bayesian posterior, with a sufficient burn-
in and update the chain sufficiently in-between to ensure subsequent draws are
independent. The sampler is initiated using the Expectation-Maximization (EM)
algorithm.
(c) Use the draws in step 2 to form the joint distribution of each deviating individual’s
observed and missing outcome data as required. This can be done under a range
of assumptions, in order to explore the robustness of inference about treatment
effects. The options presented in Carpenter et al. (2013) that each translate to a
relevant assumption are described in Table 1.
(d) Construct the conditional distribution of missing (post-deviation) given observed
outcome data for each individual who deviated, using their joint distribution formed
in step 3. Sample their missing post-deviation data from this conditional distribu-
tions to create a completed data set.
(e) Repeat steps 2–4 K times, resulting in K imputed data sets.
We now describe how step 3 works under ‘jump to reference’. This leads to a brief
presentation of the approach for the other options. Suppose there are two arms, active
(indexed below by a) and reference (indexed below by r). In step 2, denote the current
draw from the posterior for the 1+J reference arm means and variance-covariance matrix
by µr,0, . . . µr,J , and Σr. Use the subscript a for the corresponding draws from the other
arm in question (which will depend on the arm chosen as reference for the analysis at
hand).
Under ‘jump to reference’, suppose patient i is not randomised to the reference arm
and their last observation, prior to deviating, is at time di, di ∈ (1, . . . , J − 1). The joint
distribution of their observed and post-withdrawal outcomes is multivariate normal with
mean
µ˜i = (µa,0, . . . , µa,di , µr,di+1, . . . , µr,J)
T ;
that is post-deviation they ‘jump to reference’.
We construct the new covariance matrix for these observations as follows. Denote
the covariance matrices from the reference arm (without deviation) and the other arm
in question (without deviation), partitioned at time di according to the pre- and post-
deviation measurements, by:
Reference Σr =
[
R11 R12
R21 R22
]
and other arm: Σa =
[
A11 A12
A21 A22
]
.
We want the new covariance matrix, Σ say, to match that from the active arm for the
pre-deviation measurements, and the reference arm for the conditional components for
the post-deviation given the pre-deviation measurements. This also guarantees positive
definiteness of the new matrix, since Σr and Σa are positive definite. That is, we want
Σ =
[
Σ11 Σ12
Σ21 Σ22
]
,
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subject to the constraints
Σ11 = A11,
Σ21Σ
−1
11 = R21R
−1
11 ,
Σ22 −Σ21Σ−111 Σ12 = R22 −R21R−111 R12.
The solution is:
Σ11 = A11,
Σ21 = R21R
−1
11 A11,
Σ22 = R22 −R21R−111 (R11 −A11)R−111 R12.
Under ‘jump to reference’ we have now specified the joint distribution for a patient’s
pre- and post-deviation outcomes, when deviation is at time di. This is what we require
for step 4. For ‘copy increments in reference’ we use the same Σ as for ‘jump to reference’
but now
µi = {µa,0, . . . , µa,di−1, µa,di , µa,di + (µr,di+1 − µr,di),
µa,di + (µr,di+2 − µr,di), . . .}T .
For ‘last mean carried forward’, Σ equals the covariance matrix from the randomisation
arm. The important change is the way we put together µ. Thus, for patient i in arm a
under ‘last mean carried forward’,
µi = (µa,0, . . . , µa,di−1, µa,di , µa,di , . . . ...)
T ; Σ = Σa.
Finally for ‘copy reference’ the mean and covariance both come from the reference (typ-
ically, but not necessarily, control) arm, irrespective of deviation time. A SAS macro
implementing this approach can be downloaded from,
www.missingdata.org.uk (Roger, 2012) and Stata software from
https://ideas.repec.org/c/boc/bocode/s457983.html (Cro, 2015; Cro et al., 2016).
B. Appendix B: Proofs
B.1. Proof of Proposition 1
Here we outline the argument for Proposition 1. Consider the baseline (time 1) and J−1
follow-up setting where Yz,i,j denotes the continuous outcome measure for patient i in
arm z (z = a indicates active arm allocation and z = r reference arm allocation) at time
j for i = 1, ..., n and j = 1, ..., J . nd,j patients deviate at time j in a monotone fashion,
for j > 1 such that nd =
∑J
j=2 nd,j . Interest lies in the unadjusted mean treatment
group difference at time J . Conditioning on nd,j for j > 1, the expected value of the
treatment estimate at time J when the post-deviation data can be observed is,no
n
µa,J +
J∑
j=2
nd,j
n
µd,j,J
− µr,1.
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The variance of this estimate is calculated using the usual sample variance formula as,
1
n−1
∑n
i=1
(
Yr,i,J − Y¯r,J
)2
n
+
1
n−1
∑n
i=1
(
Ya,i,J − non Y¯a,J,o −
∑J
j=2
nd,j
n Y¯a,J,d,j
)2
n
where Y¯r,J =
1
n
∑n
i=1 Yr,i,J , Y¯a,J,o =
1
no
∑
i∈o Ya,i,J and Y¯a,J,d,j =
1
nd,j
∑
i∈d,j Ya,i,J for
j = 2, ..., J . When expanding this expression and letting (n− 1)→ n this has expected
value,
E
[
Vˆfull, sensitivity
]
=
σ2J,J
n
+
σ2J,J
n
+
J∑
j=2
nond,j∆
2
d,j
n3
+
J∑
p=2
J
q 6=p∑
q=2
nd,pnd,q∆
2
d,p,q
n3
where ∆d,j = µa,J − µd,j,J ,∆d,p,q = µd,p,J − µd,q,J , µd,j,J is the mean proposed under
the controlled scenario at time J , for patients who deviate at time j and µd,p,J and
µd,q,J are the means proposed under the controlled scenario at time J , for patients who
deviate at times p and q for p = 2, ..., J and q = 2, ..., J . For the δ-method of MI where
imputed values at final time J are edited by (J + 1 − j)δ, for patients who deviate at
time j, we replace ∆d,j = µa,J − µd,j,J = (J + 1 − j)δ and ∆d,p,q = µd,p,J − µd,q,J =
(J + 1− p)δ − (J + 1− q)δ.
B.2. Proof of Theorem 1
Let D and O define the sets of indices for the patients who do and do not deviate
in the active arm respectively. Further let DJ denote the set of indices for deviating
patients who deviate at time j, so that the total number of deviating patients in the
active arm nd =
∑J
j=2 nd,j . The follow-up outcome data at the final time point for the
reference patients are contained in the vector Yr,J = (Yr,1,J , ...Yr,n,J)
T . The final visit
outcome data for the observed non-deviating active patients are contained in the vector
Ya,J,o = {Ya,i,J ; i ∈ O}T .
We suppose that each deviating patient has two potential outcomes at time J : the
one that would occur if they remain on active treatment post-deviation (primary on-
treatment data model, indexed below with the subscript P ) and the other that would
occur under the controlled sensitivity scenario data model (indexed below with the sub-
script S). The potentially observable primary on-treatment data for the nd deviating
patients at time J are contained in the vector Ya,J,P,d and the alternative outcome data
under the sensitivity scenario in the vector Ya,J,S,d. Define
Y = (Yr,J ,Ya,J,o,Ya,J,P,d,Ya,J,S,d)
T as the collection of observed and potentially ob-
servable outcome data at time J , which has dimensions [(n+ no + 2nd)× 1].
For each deviating patient we can only observe one of the potential outcomes, either
primary on-treatment or under the sensitivity scenario. Consider two
[(n+ no + 2nd)× (n+ no + 2nd)] matrices, DP and DS of 0’s and 1’s such that DPY
gives the [(n+ no + 2nd)× 1] on-treatment (primary) data and DSY
gives the [(n+ no + 2nd)× 1] sensitivity scenario data at time J .
Let a be a [(n+ no + 2nd)× 1] vector such that aTDPY returns the primary on-
treatment treatment estimate and aTDSY returns the sensitivity scenario treatment
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estimate. When the deviating patients experience primary on-treatment behaviour post-
deviation and are fully observed the expectation of the variance of the primary on-
treatment estimand can be expressed as,
E
[
Vˆfull, primary
]
= E [ V
(
aTDPY
)]
= E
[
aTDP V (Y)D
T
Pa
]
= aTDPΣD
T
Pa. (7)
Under the conditions of Proposition 1 and using Corollary 1 and 2, the variance estimator
for the sensitivity estimand where post-deviation data are fully observed can be expressed
as,
E
[
Vˆfull, sensitivity
]
= aTDPΣD
T
Pa +O(n
−2). (8)
We now suppose that post-deviation data are unobserved, i.e. the potentially observ-
able primary on-treatment and sensitivity scenario entries in Y are missing for the nd
active patients. We alternatively multiply impute these outcomes, using primary on-
treatment (MAR) imputation and imputation under the sensitivity scenario. This gives
K ‘complete’ data samples Yk, of size [(n+ no + 2nd)× 1]. For this we need appro-
priate imputation distributions for each missing data pattern under each scenario, with
suitable posteriors for the included parameters.
Under our primary on-treatment assumption (MAR), the imputation model for pa-
tients deviating at time j, for each j > 1 is formed from the regression of Ya,J,o on Pa,o,j
where Pa,o,j is the design matrix for the imputation model, which contains the values
of the 1, ..., j − 1 outcomes and covariates included in the imputation model (excluding
treatment) for the no observed active patients, along with a vector of 1’s to include
an intercept in the model. This is appropriate since we are not imputing any interim
missing outcomes here. We only consider monotone missing data patterns. We are in-
terested in the treatment effect at time J . As described by Carpenter and Kenward
(2013, p. 77–78), under MAR, each of the regressions will be validly estimated from
those observed in the data set. The parameter estimates for the primary on-treatment
(MAR) imputation model for the nd,j patients missing outcomes j to J for each j > 1
are found as βˆprimary,j = (P
T
a,o,jPa,o,j)
−1PTa,o,jYa,J,o with assumed known covariance
matrix Vprimary,j = (P
T
a,o,jPa,o,j)
−1σ2j .
We assume the large sample posterior for the parameter estimates for the primary
on-treatment imputation model, denoted βˆprimary,j , is normal and centered on the ML
estimator βˆprimary,j with covariance matrix Vprimary,j . That is,
βˆprimary,j |Ya,J,o ∼ N(βˆprimary,j ; Vprimary,j).
The primary on-treatment imputation model for active patient i deviating at time j, for
each j > 1 and imputation k can therefore be expressed as,
Y˜a,i,J,k|Ya,J,o = Pa,d,j,i
[
βˆprimary,j + bprimary,j,k
]
+ ei,j,k for i ∈ {DJ },
where, bprimary,j,k ∼ N(0,Va,o,j), ei,j,k ∼ N(0, σ2j ) and Pa,d,j,i contains the values of
the 1, ..., j − 1 outcomes and covariates included in the imputation model (excluding
treatment, plus a 1 for the intercept) for each deviating active patient i, who deviates
at time j.
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For sensitivity analysis we conduct imputation under the proposed sensitivity scenario
and assume the large sample posterior for the imputation parameters for the nd,j patients
missing outcomes j to J for each j > 1, βˆsensitivity,j is normal and centered on the ML
estimator βˆsensitivity,j with known covariance matrix Vsensitivity,j , that is for each j > 1,
βˆsensitivity,j |Ysensitivity,J ∼ N(βˆsensitivity,j ; Vsensitivity,j),
where Ysensitivity,J consists of the relevant observed outcome data under the particular
sensitivity scenario setting of interest. The imputation model used in the sensitivity
analysis for active patient i deviating following time j, for each j > 1 and imputation k
can therefore be expressed as,
Y˘a,i,J,k|Ysensitivity,J = Pa,d,j,i
[
βˆsensitivity,j + bsensitivity,j,k
]
+ ei,j,k for i ∈ {DJ },
where, bsensitivity,j,k ∼ N(0,Vsensitivity,j) and ei,j,k ∼ N(0, σ2j ). Under the assumption
of equal variance-covariance matrix of baseline and follow-up by treatment arm we con-
sequently assume the same variance for the residuals in the primary and sensitivity
imputation models for patients deviating at the same time j, for each j > 1.
We are interested in imputation inference for, 1K
∑K
k=1 a
TDPYk or
1
K
∑K
k=1 a
TDSYk.
Letting the number of imputations, K → ∞, the variance of our MI treatment esti-
mate as estimated by Rubin’s rules is, VˆMI, primary = Wˆprimary + Bˆprimary or VˆMI, sensitivity =
Wˆsensitivity + Bˆsensitivity where under the conditions required in the proposition,
E
[
Wˆprimary
]
= E
[
1
K
∑K
k=1 a
TDPΣˆkD
T
Pa
]
→ aTDPΣDTPa and,
E
[
Wˆsensitivity
]
= E
[
1
K
∑K
k=1 a
TDSΣˆkD
T
S a
]
→ aTDPΣDTPa +O(n−2).
Under primary (on-treatment) imputation,
Bˆprimary =
1
K − 1
K∑
k=1
 J∑
j=2
pid,j (e¯j,k − e¯j) + pid,j
(
P¯a,d,jbprimary,j,k − P¯a,d,jb¯primary,j
)2
where e¯j,k =
1
nd,j
∑
i∈DJ ei,j,k, e¯j =
1
K
∑K
k=1 e¯j,k, P¯a,d,j =
1
nd,j
∑
i∈DJ Pa,d,j,i and
b¯primary,j =
1
K
∑K
k=1 bprimary,j,k. Which has expectation,
E
[
Bˆprimary
]
=
∑J
j=2 pi
2
d,j
[
σ2j+nd,jP¯a,d,jVprimary,jP¯
T
a,d,j
nd,j
]
.
When imputation is conducted under the sensitivity scenario,
Bˆsensitivity =
1
K − 1
K∑
k=1
 J∑
j=2
pid,j (e¯j,k − e¯j) + pid,j
(
P¯a,d,jbsensitivity,j,k − P¯a,d,jb¯sensitivity,j
)2 ,
where b¯sensitivity,j =
1
K
∑K
k=1 bsensitivity,j,k. Which has expectation,
E
[
Bˆsensitivity
]
=
∑J
j=2 pi
2
d,j
[
σ2j+nd,jP¯a,d,jVsensitivity,jP¯
T
a,d,j
nd,j
]
.
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The information-anchored variance can be expressed as,
E
[
Vˆanchored
]
=
E
[
Vˆfull, sensitivity
] (
E
[
Wˆprimary
]
+ E
[
Bˆprimary
])
E
[
Vˆfull, primary
] = E [Vˆfull, sensitivity]
1 + E
[
Bˆprimary
]
E
[
Wˆprimary
]
 .
Since E
[
Wˆprimary
]
= E
[
Vˆfull, primary
]
and using (7) and (8) that is,
E
[
Vˆanchored
]
= aTDPΣD
T
Pa +O(n
−2) +
E
[
Bˆprimary
]
E
[
Wˆprimary
] [aTDPΣDTPa +O(n−2)]
= aTDPΣD
T
Pa +O(n
−2) + E
[
Bˆprimary
]
+
E
[
Bˆprimary
]
E
[
Wˆprimary
]O(n−2).
If Rubin’s rules are information-anchoring and preserve the information loss in the pri-
mary analysis under MAR then the following holds,
E
[
Wˆsensitivity
]
+E
[
Bˆsensitivity
]
≈ aTDPΣDTPa+O(n−2)+E
[
Bˆprimary
]
+
E
[
Bˆprimary
]
E
[
Wˆprimary
]O(n−2).
That is,
aTDPΣD
T
Pa +O(n
−2) + E
[
Bˆsensitivity
]
≈ aTDPΣDTPa +O(n−2)
+E
[
Bˆprimary
]
+
E
[
Bˆprimary
]
E
[
Wˆprimary
]O(n−2).
After simplification and rearrangement this becomes,
0 ≈ E
[
Bˆprimary
]
− E
[
Bˆsensitivity
]
+
E
[
Bˆprimary
]
E
[
Wˆprimary
] [O(n−2)] .
Which is,
0 ≈
J∑
j=2
[
pi2d,jP¯a,d,j (Vprimary,j −Vsensitivity,j) P¯Ta,d,j
]
+
E
[
Bˆprimary
]
E
[
Wˆprimary
] [O(n−2)]
This gives the required result in the longitudinal trial setting with monotone miss-
ingness in the active treatment arm with K = ∞. In practice K 6= ∞, however
the information-anchoring approximation results will still hold for finite K. For fi-
nite K the variance of our MI treatment estimate as estimated by Rubin’s rules is,
VˆMI, primary = Wˆprimary +
(
1 + 1K
)
Bˆprimary or VˆMI, sensitivity = Wˆsensitivity +
(
1 + 1K
)
Bˆsensitivity. We
will therefore have additional terms in the difference between Rubin’s variance estimator
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and the ideal information-anchored variance, but these will also be very small. They
will be the same order of the terms already presented multiplied by K−1, hence in-
deed smaller. Thus following the reasons discussed in the main text the approximation
remains with finite K.
We note that when we relax the equal variance by trial arm assumption, we can no
longer assume the variance of the residuals in the primary de jure imputation model
for patients with missingness pattern j matches the variance of the residuals in the
sensitivity de facto imputation model for patients with missingness pattern j, for each
missing data pattern j.
In this setting we denote the variance of the residuals in the primary on-treatment
imputation model for patients missing outcomes j, ..., J as σ2P,j and in the sensitivity
imputation model as σ2S,j for j > 1. Then the information-anchoring performance of
Rubin’s MI variance estimator is driven by,
0 ≈
J∑
j=2
pi2d,j
[
σ2P,j − σ2S,j
nd,j
+ P¯a,d,j (Vprimary,j −Vsensitivity,j) P¯Ta,d,j
]
+
E
[
Bˆprimary
]
E
[
Wˆprimary
] [O(n−2)] .
The additional components in the difference between Rubin’s variance and the ideal
information-anchored variance are driven by the degree of difference in the variance
structure of the data by trial arm for each missingness pattern. Since the variance
structure is not likely to differ too markedly by trial arm for each missingness pattern,
and these extra components are each multiplied by pi2d,j/nd,j , the overall impact will in
practice be relatively small.
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C. Appendix C: Further simulation results
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Fig. 4. Simulation results: for each sensitivity scenario, as the proportion of active arm devia-
tions increases, each panel shows the evolution of the mean estimate of the visit 3 treatment
effect variance (over 1000 simulations) calculated in four ways: (i) −◦− Rubin’s MI variance, from
reference-/δ-based MI; (ii) −×− Information-anchored variance (Eˆ[Vˆanchored]); (iii) −− applying pri-
mary analysis variance estimator in sensitivity scenarios; (iv) −/− Variance when post-deviation
data is alternatively fully observed under the given scenario (Eˆ[Vˆfull, sensitivity]).
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